Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial

Atypical meningioma is a tumour that arises from the lining of the brain. It mostly affects adults, with most patients in the 40-60 year age group. The primary treatment for atypical meningioma is surgical removal, but with surgery alone up to 40% of patients will experience recurrence. Because of this risk, some clinicians give early radiotherapy, whilst others advise regular monitoring with radiotherapy given only at recurrence. Currently there is no consensus as to which of these two approaches is best. This randomised controlled trial will compare the two approaches, and aims to determine whether early radiotherapy reduces the risk of tumour recurrence compared to regular monitoring in newly diagnosed atypical meningioma.

Primary Sponsor

The Walton Centre NHS Foundation Trust, University of Liverpool, UK

Collaborating Groups

European Organisation for Research and Treatment of Cancer (EORTC) ; Trans Tasman Radiation Oncology Group (TROG)

Final Accrual

15

Closing Date of Accrual

May 2021

Trial Chairperson

Dr Neda Haghighi, Peter MacCallum Cancer Centre, VIC

Trial Contact

ROAM@trog.com.au

Related Post

DECREASE trial into prostate cancer
8 July, 2025

Recruitment Milestone Achieved for TROG 19.06 DECREASE Trial

TRIAL UPDATE: 8 July 2025 The TROG 19.06 DECREASE

Geoff Zipper - aka Swamp - on the Kokoda Trail
26 June, 2025

Cancer Survivor to Take on Fifth Kokoda trek to Support TROG

LATEST NEWS: 26 June 2025 He may be 76